Mercaptopurina Zentiva

Mercaptopurine, the active ingredient in Mercaptopurina Zentiva, is a purine analog antimetabolite presented as a strength/form for oral use. It treats acute lymphoblastic leukemia and inflammatory bowel disease in both adult and pediatric patients.

GNH USA supplies Mercaptopurina Zentiva as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Mercaptopurine acts as a purine analog used in hematologic malignancies and immune‑mediated gastrointestinal disorders. - Acute lymphoblastic leukemia: induces remission and supports long‑term disease control. - Maintenance therapy for leukemia: sustains remission and reduces relapse risk. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): helps achieve and maintain clinical remission in moderate to severe cases.

Adverse reactions may range from mild to severe and require monitoring.

Common Side Effects: - Nausea and vomiting - Loss of appetite - Mild elevation of liver enzymes - Fatigue - Mild infections - Diarrhea

Serious or Rare Side Effects: - Severe bone‑marrow suppression (neutropenia, anemia, thrombocytopenia) - Hepatotoxicity with marked liver injury - Pancreatitis - Life‑threatening hypersensitivity reactions - Secondary malignancies - Severe infections such as sepsis

Use of Mercaptopurina Zentiva requires careful clinical oversight. - Monitor blood counts: perform regular CBC to detect myelosuppression. - Assess liver function: periodic LFTs to identify hepatotoxicity. - Adjust dose in renal impairment: reduce dosage when creatinine clearance is decreased. - Avoid in pregnancy: drug is teratogenic (Category D) and should not be used unless essential. - Use effective contraception: both male and female patients must employ reliable birth control. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Mercaptopurina Zentiva can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Allopurinol: markedly increases risk of myelosuppression. - Warfarin: potentiates anticoagulant effect, raising bleeding risk. - Live vaccines: heightened risk of infection due to immunosuppression. - Methotrexate: additive bone‑marrow toxicity.

Moderate Interactions (Monitor Closely): - Azathioprine: shared metabolic pathway may increase toxicity. - Rifampin: may reduce mercaptopurine plasma concentrations. - NSAIDs: can affect renal function and increase toxicity risk.